Veradermics, Incorporated (MANE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Veradermics, Incorporated stock (MANE) is currently trading at $65.56. Analyst consensus price target for MANE is $78.33. WallStSmart rates MANE as Sell.
- MANE PE ratio analysis and historical PE chart
- MANE PS ratio (Price-to-Sales) history and trend
- MANE intrinsic value — DCF, Graham Number, EPV models
- MANE stock price prediction 2025 2026 2027 2028 2029 2030
- MANE fair value vs current price
- MANE insider transactions and insider buying
- Is MANE undervalued or overvalued?
- Veradermics, Incorporated financial analysis — revenue, earnings, cash flow
- MANE Piotroski F-Score and Altman Z-Score
- MANE analyst price target and Smart Rating
Veradermics, Incorporated
📊 No data available
Try selecting a different time range
Smart Analysis
Veradermics, Incorporated (MANE) · 2 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Significant fundamental concerns warrant caution or avoidance.
Veradermics, Incorporated (MANE) Key Strengths (1)
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Veradermics, Incorporated (MANE) Areas to Watch (1)
Moderate institutional interest at 44.96%
Veradermics, Incorporated (MANE) Detailed Analysis Report
Overall Assessment
This company scores 10/100 in our Smart Analysis, earning a F grade. Out of 2 metrics analyzed, 1 register as strengths (avg 7.0/10) while 1 fall into concern territory (avg 6.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap.
The Bear Case
The primary concerns are Institutional Own..
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Institutional Own. improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MANE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Insider Transactions
Loading insider activity...
About Veradermics, Incorporated(MANE)
NYSE
HEALTHCARE
BIOTECHNOLOGY
USA
Veradermics, Incorporated is a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company is headquartered in New Haven, Connecticut.